MIRA Pharmaceuticals, Inc.

As of June 30, 2026, MIRA Pharmaceuticals, Inc. carries a market capitalization of 35.09M, placing it among publicly traded companies globally. Its enterprise value stands at 27.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MIRA Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, MIRA Pharmaceuticals, Inc. has 42.02M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MIRA Pharmaceuticals, Inc. maintains a current ratio of 200.08, meaning it holds 200.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, MIRA Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -217.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -209.00, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, MIRA Pharmaceuticals, Inc.'s stock has declined approximately 53.67% over the past 52 weeks. The 50-day moving average sits at 0.67, while the 200-day moving average is 0.85.

Over the twelve months ended June 30, 2026, MIRA Pharmaceuticals, Inc. generated - - in revenue and converted that into -8.30M in net income, yielding earnings per share of -0.23. EBITDA reached -8.23M, while operating income came in at -8.23M.

These figures are as of June 30, 2026. Total book value stands at 7.14M, with working capital of 7.11M providing operational flexibility.

MIRA Pharmaceuticals, Inc. produced -4.06M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.75, meaning MIRA Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, MIRA Pharmaceuticals, Inc. has an Altman Z-Score of 579.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.